Sanofi (NASDAQ:SNY) Stake Reduced by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB cut its holdings in Sanofi (NASDAQ:SNY) by 12.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,334 shares of the company’s stock after selling 461 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Sanofi were worth $161,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in Sanofi during the 4th quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new stake in Sanofi during the 3rd quarter worth about $29,000. Concord Wealth Partners raised its holdings in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the period. Fortitude Family Office LLC raised its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. Finally, Sunbelt Securities Inc. raised its holdings in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Trading Up 1.2 %

Shares of NASDAQ SNY opened at $54.56 on Thursday. The stock has a market cap of $138.46 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 0.99 and a beta of 0.57. The business has a 50 day simple moving average of $50.07 and a 200 day simple moving average of $52.41. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.